Labcorp (NYSE:LH) Updates FY 2026 Earnings Guidance

Labcorp (NYSE:LH - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 17.700-18.350 for the period, compared to the consensus estimate of 17.760. The company issued revenue guidance of $14.7 billion-$14.8 billion, compared to the consensus revenue estimate of $14.7 billion.

Analyst Ratings Changes

A number of brokerages have weighed in on LH. Wall Street Zen lowered Labcorp from a "buy" rating to a "hold" rating in a research report on Saturday, April 4th. Weiss Ratings raised Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, February 10th. Evercore restated an "outperform" rating and set a $300.00 price target on shares of Labcorp in a research note on Wednesday, April 8th. Robert W. Baird upped their price objective on shares of Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 18th. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Labcorp in a report on Tuesday, February 17th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Labcorp has an average rating of "Moderate Buy" and a consensus price target of $307.20.

Labcorp Price Performance

Shares of LH stock opened at $257.38 on Thursday. Labcorp has a fifty-two week low of $234.15 and a fifty-two week high of $293.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The firm has a market capitalization of $21.15 billion, a price-to-earnings ratio of 24.61, a PEG ratio of 1.80 and a beta of 1.02. The stock's 50-day simple moving average is $271.20 and its 200-day simple moving average is $267.56.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.10 by $0.15. The firm had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities analysts forecast that Labcorp will post 17.67 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Friday, May 29th. Labcorp's payout ratio is presently 27.53%.

Insider Activity at Labcorp

In other news, EVP Der Vaart Sandra D. Van sold 548 shares of the business's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $284.91, for a total transaction of $156,130.68. Following the sale, the executive vice president directly owned 2,579 shares of the company's stock, valued at $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Adam H. Schechter sold 8,705 shares of the company's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total value of $2,437,051.80. Following the completion of the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at approximately $22,613,209.08. The trade was a 9.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,113 shares of company stock valued at $4,547,450 over the last three months. 0.84% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Labcorp

A number of large investors have recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in shares of Labcorp in the 4th quarter valued at $991,000. Evolve Private Wealth LLC acquired a new stake in shares of Labcorp in the fourth quarter worth $243,000. Armistice Capital LLC purchased a new position in shares of Labcorp during the fourth quarter worth $229,000. B. Riley Wealth Advisors Inc. acquired a new position in Labcorp during the second quarter valued at $210,000. Finally, Federated Hermes Inc. lifted its position in Labcorp by 43.2% during the fourth quarter. Federated Hermes Inc. now owns 517 shares of the medical research company's stock valued at $130,000 after purchasing an additional 156 shares during the period. Hedge funds and other institutional investors own 95.94% of the company's stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.